The Biologics News and Reports Portal

Show Cart

Immuno-Oncology

Results 1 - 12 of 12

Sep 2023 CCR8-Targeted Antibody Immunotherapy Pipeline Review

300.00 €

Aug 2023 CD40 Agonists & CD40/L Antagonists Pipeline Review

300.00 €

Mar 2023 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

120.00 €

Jul 2018 Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

800.00 €

Jul 2018 Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

500.00 €

Jun 2018 Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

500.00 €

Jun 2018 Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

600.00 €

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

2,150.00 €

Shopping cart

Cart empty

Latest report

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

DLL3-Targeted Immunotherapy Candidates Pipeline Review

Shopping cart

Cart empty

Latest report

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Immuno-Oncology

Sep 2023 CCR8-Targeted Antibody Immunotherapy Pipeline Review

Aug 2023 CD40 Agonists & CD40/L Antagonists Pipeline Review

Mar 2023 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Apr 2020 STING Agonists & Antagonists – Target Pipeline List 04/2020

Feb 2020 TIGIT-Targeted Immunotherapeutics – Target Pipeline List 02/2020

Sep 2019 Competitor Analysis: TGF-beta/Receptor Inhibitors

Jul 2019 CD137 Costimulatory Receptor Agonists – Target Pipeline List 07/2019

Jul 2018 Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

Jul 2018 Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

Jun 2018 Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

Jun 2018 Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing